913168-10-2 Usage
Description
Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate is a complex chemical compound that features a benzo[d][1,2,3]triazole ring, a carbonate group attached to an ethyl chain, and a pyridine disulfide. Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate is characterized by its intricate molecular structure, which may confer specific targeting and interaction capabilities within biological systems.
Uses
Used in Chemical Research:
Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate is utilized as a research tool in chemical studies, where its unique structure can be explored for understanding molecular interactions and the development of new methodologies.
Used in Drug Development:
In the pharmaceutical industry, Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate is employed as a lead compound for drug development. Its potential biological and pharmacological activities make it a promising candidate for further research and the creation of novel therapeutic agents.
Further research is necessary to fully elucidate the chemical properties and potential applications of Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate, ensuring its safe and effective use in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 913168-10-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,3,1,6 and 8 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 913168-10:
(8*9)+(7*1)+(6*3)+(5*1)+(4*6)+(3*8)+(2*1)+(1*0)=152
152 % 10 = 2
So 913168-10-2 is a valid CAS Registry Number.
913168-10-2Relevant articles and documents
CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER
-
, (2021/01/29)
Ligand-drug conjugates for targeted melanoma therapies are disclosed herein. A ligand is conjugated to a cytotoxic cancer drug through a cleavage linker. The ligand can bind to an overexpressed receptor on a cancer cell, resulting in selectivity. This allows the drug to enter a cancer cell selectively and release the drug within that specific cancer cell. Such therapies provide selectivity to melanoma through a ligand that targets the MC1R receptor, which is highly expressed in 80% of malignant melanomas. The ligand-drug conjugates can be used to deliver a wide range of cytotoxic cancer drugs selective to melanoma cells which may solve the drug resistance problem of melanoma in current therapies.
Novel mTOR inhibitor compounds and the use thereof
-
Paragraph 0113-0118; 0146-0148, (2021/03/16)
The novel mTOR inhibitor compounds of the present invention are capable of selective drug delivery to bone and released slowly in bone for a long period of time. The present invention relates to a targeted compound linked to a mTOR inhibitory bone disease therapeutic agent.
A Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinase Inhibitors
Kraj?ovi?ová, Soňa,Gucky, Tomá?,Hendrychová, Denisa,Kry?tof, Vladimír,Soural, Miroslav
, p. 13530 - 13541 (2017/12/15)
Herein, we report an alternative synthetic approach for selected 2,6,9-trisubstituted purine CDK inhibitor conjugates with folic acid as a drug-delivery system targeting folate receptors. In contrast to the previously reported approaches, the desired conj
